Global Pen Needles Market 2017-2021


◆タイトル:Global Pen Needles Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥399,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥570,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About Pen NeedlesThe delivery of injectable medications into the body with pen devices are done with the help of pen needles. Advances in technology are causing a shift in end-user preference from invasive procedures to minimally and non-invasive procedures. Pen needles are mainly used by individuals with diabetes who require multiple daily injections. Pens are preferred for drug delivery due to its user-friendliness and ease of use compared to syringes. The high cost of pens compared to syringes is the main challenge to the adoption of these devices. North American countries such as the US and Canada are the major revenue contributors due to the favorable reimbursement policies for pen needles.

Technavio’s analysts forecast the global pen needles market to grow at a CAGR of 10.06% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global pen needles market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of pen needle products.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Pen Needles Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• BD
• Novo Nordisk
• Ypsomed
• B. Braun

[Other prominent vendors]
• Allison Medical
• Artsana
• Beipu Medicals
• Henso Medical
• Medtronic
• Medline
• Menarini Diagnostics
• Owen Mumford
• Pietrasanta
• Simple Diagnostics
• Stat Medical
• Terumo
• Trividia Health
• UltiMed

[Market driver]
• Increasing preference for pen needles over syringes and vials
• For a full, detailed list, view our report

[Market challenge]
• Shortage of endocrinologists
• For a full, detailed list, view our report

[Market trend]
• Technological advances in non-invasive techniques
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 06: Market segmentation by product
• Market overview
• Standard pen needles
• Safety pen needles

PART 07: Market segmentation by therapy
• Market overview

PART 08: Market segmentation by end-user
• Market overview
• Hospitals and clinics
• Home care

PART 09: Geographical segmentation
• Market overview
• Pen needles market in Americas
• Pen needles market in EMEA
• Pen needles market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Technological advances in non-invasive techniques
• Strategic alliances for product innovation
• Shift in market focus toward emerging countries

PART 13: Vendor landscape
• Competitive analysis

PART 14: Key vendor analysis
• BD
• Novo Nordisk
• Ypsomed
• B. Braun
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Global pen needles market: Market derivation 2016
Exhibit 02: Market overview: Global pen needles market 2016
Exhibit 03: Global pen needles market 2016-2021 ($ millions)
Exhibit 04: Five forces analysis
Exhibit 05: Global pen needles market by product 2016 (%)
Exhibit 06: Market overview of standard pen needles
Exhibit 07: Global standard pen needles market 2016-2021 ($ millions)
Exhibit 08: Market overview of safety pen needles
Exhibit 09: Global safety pen needles market 2016-2021 ($ millions)
Exhibit 10: Global pen needles market by therapy 2016
Exhibit 11: Global pen needles market by end-user 2016
Exhibit 12: Global pen needles market by end-users 2016
Exhibit 13: Buying criteria: Global pen needles market by end-user 2016
Exhibit 14: Global pen needles market by geography 2016 and 2021 ($ millions)
Exhibit 15: Market overview of pen needles market in Americas 2016
Exhibit 16: Pen needles market in Americas 2016-2021 ($ millions)
Exhibit 17: Americas: Market metrics in key countries
Exhibit 18: Market overview of pen needles market in EMEA in 2016
Exhibit 19: Pen needles market in EMEA 2016-2021 ($ millions)
Exhibit 20: Market overview of pen needles market in APAC 2016
Exhibit 21: Pen needles market in APAC 2016-2021 ($ millions)
Exhibit 22: Cost comparison of pen needles and syringe needles
Exhibit 23: Prevalence rate of diabetes in age group of 20-79 in select countries 2013
Exhibit 24: NANOPASS by Terumo: Compatibility with pen needles by other vendors
Exhibit 25: Competitive structure analysis of global pen needles market
Exhibit 26: Market penetration of various global pen needles providers 2017
Exhibit 27: Strategic success factors of companies in global pen needles market 2017
Exhibit 28: BD: Key highlights
Exhibit 29: BD: Strength assessment
Exhibit 30: BD: Strategy assessment
Exhibit 31: BD: Opportunity assessment
Exhibit 32: Novo Nordisk: Key highlights
Exhibit 33: Novo Nordisk: Strength assessment
Exhibit 34: Novo Nordisk: Strategy assessment
Exhibit 35: Novo Nordisk: Opportunity assessment
Exhibit 36: Ypsomed: Key highlights
Exhibit 37: Ypsomed: Strength assessment
Exhibit 38: Ypsomed: Strategy assessment
Exhibit 39: Ypsomed: Opportunity assessment
Exhibit 40: B. Braun: Key highlights
Exhibit 41: B. Braun: Strength assessment
Exhibit 42: B. Braun: Strategy assessment
Exhibit 43: B. Braun: Opportunity assessment


BD, Novo Nordisk, Ypsomed, B. Braun, Allison Medical, Artsana, Beipu Medicals, Henso Medical, HTL-STREFA, Medtronic, Medline, Menarini Diagnostics, Owen Mumford, Pietrasanta, Simple Diagnostics, Stat Medical, Terumo, Trividia Health, and UltiMed.